Leading healthcare information technology ("HCIT") solutions
) recently reported that it launched its positive patient
identification ("PPID") system to enhance medical outcomes at
Corniche Hospital in the United Arab Emirates ("UAE"). The hospital
is Cerner's first customer in that country with a complete
closed-loop medication administration system. Due to this system,
drugs may be administered to the patient in congruence with
The PPID initiative uses bar code know-how with a hand-held
instrument which reads from the wristband of the patient. It
confirms data in the electronic health/medical record ("EHR/EMR")
of the patient operated by Cerner's Millennium technology. This
PPID program is in consonance with the benchmarks set by the Joint
Commission International ("JCI").
The closed loop medication system, to provide automated
validation of drugs, has been launched in one nursing unit of the
hospital. Corniche Hospital has been qualified for Stage 6
certification in the HIMSS Analytics EMR Adoption Model ("EMRAM").
Consequently, it was conferred with HIMSS 6 recognition at the
EMRAM Awards Ceremony at the yearly HIMSS Mid East Conference and
Leadership Summit held on May 20, at Abu Dhabi. The hospital is
Cerner's second customer, located in the Mid East, to achieve HIMSS
Stage 6 qualification.
We believe long-term investors may consider Cerner, which serves
a sizeable installed hospital base that requires composite
clinically-focused applications complying with "meaningful use"
requirements, reimbursement problems and complex coding issues. The
company has long-standing, integrated and seamless solutions for
both inpatient and ambulatory settings.
On the negative side, the federal Stimulus program will
gradually wind down. Cerner faces stiff competition from
established HCIT players, such as
) and many others in a crowded field.
ATHENAHEALTH IN (ATHN): Free Stock Analysis
CERNER CORP (CERN): Free Stock Analysis Report
ALLSCRIPTS HLTH (MDRX): Free Stock Analysis
QUALITY SYS (QSII): Free Stock Analysis Report
To read this article on Zacks.com click here.